Want to see GRI full AI Analyst Report?
GRI Stock Chart & Stats
$1.45
-$0.05(-3.45%)
At close: 4:00 PM EDT
$1.45
-$0.05(-3.45%)
Day’s Range― - ―
52-Week Range$1.36 - $80.36
Previous CloseN/A
Volume6.87K
Average Volume (3M)82.65K
Market Cap
$2.44M
Enterprise Value-$10.78M
Total Cash (Recent Filing)$11.05M
Total Debt (Recent Filing)$58.00K
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Aug 19, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-241.87
Shares Outstanding1,770,838
10 Day Avg. Volume33,303
30 Day Avg. Volume82,652
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-4.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.39K
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$21.00Price Target Upside1348.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone - Orphan Drug DesignationOrphan designation is a durable regulatory benefit: it can yield up to seven years U.S. exclusivity, tax credits and fee waivers, and closer FDA engagement. These structural advantages improve development economics, reduce some program costs, and raise partnering and commercialization optionality over the medium term.
Positive Phase 2a Clinical DataRobust Phase 2a signals (symptom benefit, biomarker evidence, favorable safety) materially raise the probability of successful pivotal development. Strong early clinical proof and new patents enhance IP protection and make partnering, licensing or non-dilutive funding more attainable for later-stage programs.
Low Leverage And Improved Balance SheetVery low financial leverage and materially improved equity reduce near-term solvency pressure and refinancing risk relative to prior years. This structural balance sheet strength provides flexibility to prioritize clinical development and strategic options without immediate debt overhang.
Bears Say
High Cash Burn And Financing DependenceSustained negative operating and free cash flows mean the company must access external capital to advance trials and programs. That reliance is a persistent dilutive and execution risk: fundraising needs can delay programs, constrain R&D prioritization, and raise cost of capital over the medium term.
Weak And Widening ProfitabilityDeep negative margins and a widening net loss indicate that current operations are not generating sustainable earnings. Until clinical success translates into durable revenue growth or major licensing deals, negative returns on equity and volatile profitability will constrain internal funding capacity and shareholder returns.
Clinical-stage Profile And Revenue VolatilityAs a clinical-stage biotech with no commercial products, the firm's long-term prospects hinge on binary trial outcomes and regulatory decisions. That structural model creates high project concentration, revenue volatility and dependence on successful pivotal trials or partners to achieve sustained commercial cash generation.
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $1.36 and its highest was $80.36 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $2.44M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on May 14, 2026. The company reported -$1.61 earnings per share for the quarter, missing the consensus estimate of -$1.605 by -$0.005.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate is -1.2.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 1,770,838 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$1.61 in its last earnings report, missing expectations of -$1.605. Following the earnings report the stock price went down -4.867%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$21.00
▲(1348.28% Upside)
Technical Analysis
Ownership Overview
32.35%
Insiders
0.44% Mutual Funds
― Other Institutional Investors
66.00% Public Companies and
Individual Investors